Johnson & Johnson has renewed an agreement with Scripps Clinic and Research Foundation under which the New Jersey-based pharmaceutical firm will underwrite $70 million in biomedical research at the facility over the next 10 years in exchange for the rights to develop the fruits of the research for commercial use.
The new agreement, announced this week by Scripps President Charles C. Edwards, essentially renews an arrangement that has been in effect since 1982. Although Edwards said he was "obviously very delighted" that the institution will continue to have a stable source of private funding, he said he had not been worried that Johnson & Johnson would let the agreement lapse.
"I don't think it was ever considered," Edwards said. "We've established a very good, close working relationship with Johnson & Johnson over the past four-plus years."
Most of the work funded by Johnson & Johnson is basic research that can be applied to the development of both therapeutic and diagnostic drugs, Edwards said. The firm operates a research center in Sorrento Valley where findings made at Scripps are refined for commercial use.